We are live on ! Find out more
BCM

Burrage Capital Management Portfolio holdings

AUM $99.7M
1-Year Est. Return 66.05%
This Fund
S&P 500
This Quarter Est. Return
+51.27%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$143M
AUM Growth
+$41.3M
Cap. Flow
+$180K
Cap. Flow %
0.13%
Top 10 Hldgs %
59.86%
Holding
34
New
3
Increased
4
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
ADCT icon
ADC Therapeutics
ADCT
+$5.12M
2
FULC icon
Fulcrum Therapeutics
FULC
+$4.59M
3
AIMT
Aimmune Therapeutics
AIMT
+$3.74M
4
INSM icon
Insmed
INSM
+$2.37M
5
MRUS
Merus
MRUS
+$2.03M

Top Sells

Rank Stock Value
1
CTMX icon
CytomX Therapeutics
CTMX
+$3.46M
2
TVRD
Tvardi Therapeutics
TVRD
+$3.29M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$2.78M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$2.11M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$1.84M

Sector Composition

Rank Sector Weight
1 Healthcare 96.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
26
Autolus Therapeutics
AUTL
$519M
$241K 0.17%
15,006
– –
CTMX icon
27
CytomX Therapeutics
CTMX
$690M
– –
-482,982
Closed -$3.46M
IRWD icon
28
Ironwood Pharmaceuticals
IRWD
$709M
– –
-115,899
Closed -$1.17M
WVE icon
29
Wave Life Sciences
WVE
$1.13B
– –
-56,699
Closed -$556K
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.02B
– –
-200,000
Closed -$2.11M
TVRD
31
Tvardi Therapeutics
TVRD
$19M
– –
-7,188
Closed -$3.29M
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-19,502
Closed -$280K
TCDA
33
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-131,661
Closed -$2.78M
AERI
34
DELISTED
Aerie Pharmaceuticals
AERI
– –
-88,445
Closed -$1.19M
1
2

Similar funds

WCM
Weld Capital Management New York $98.8M AUM 52.83% 1-Year Est. Return
CCM
Coe Capital Management Highland Park, Illinois $106M AUM 53.24% 1-Year Est. Return
RGM
ROAM Global Management New York $117M AUM
TCM
Taal Capital Management Boston, Massachusetts $122M AUM 50.45% 1-Year Est. Return
RC
Regents Capital Hong Kong $76.8M AUM
AC
Aperimus Capital Marina Del Rey, California $62.2M AUM 47.35% 1-Year Est. Return
QVT
Quantitative Value Technologies Overland Park, Kansas $60.7M AUM
WFWM
Wechter Feldman Wealth Management Parsippany, New Jersey $143M AUM 25.17% 1-Year Est. Return

Burrage Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Burrage Capital Management held 34 positions worth $143M, up 41% from $102M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Burrage Capital Management's Q2 2020 filing shows 3 new, 4 increased, 11 reduced and 8 closed positions. Its largest new stake was ADC Therapeutics: 134,912 shares worth $6.32M. The largest sale was CytomX Therapeutics, an estimated $3.46M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

  • Burrage Capital Management's largest Q2 2020 buy was ADC Therapeutics: 134,912 shares worth $6.32M.
  • Burrage Capital Management added most to Aimmune Therapeutics in Q2 2020, an estimated $3.74M increase.
  • Burrage Capital Management's biggest Q2 2020 reduction was Y-mAbs Therapeutics, cutting an estimated $1.84M.
  • Burrage Capital Management fully exited CytomX Therapeutics in Q2 2020, selling an estimated $3.46M.
  • Burrage Capital Management's ten largest holdings make up 60% of its $143M portfolio in Q2 2020.
  • Burrage Capital Management opened 3 new positions and closed 8 in Q2 2020.
  • Burrage Capital Management's portfolio value rose 41% quarter-over-quarter to $143M.

Based on Burrage Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.